Share

August 2021; 11 (4) Commentary

COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy

Andrew Wolf, Enrique Alvarez
First published April 14, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001088
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1148

Share

Article Information

vol. 11 no. 4 358-361
DOI: 
https://doi.org/10.1212/CPJ.0000000000001088
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received January 25, 2021
  • Accepted March 18, 2021
  • First Published April 14, 2021.

Article Versions

Copyright & Usage: 
Copyright © 2021 American Academy of Neurology

Author Disclosures

    1. Andrew Wolf, MD, MS and
    2. Enrique Alvarez, MD, PhD
  1. Andrew Wolf, MD, MS and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Enrique Alvarez, MD, PhD
    3. Scientific Advisory Boards:

    1. Actelion/Janssen, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Genzyme, Novartis, Sanofi, and TG Therapeutics

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Genentech/Roche, Novartis, TG Therapeutics,

    Research Support, Government Entities:

    1. Patient-Centered Outcomes Research Initiative, National Institutes of Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society, and Rocky Mountain MS Center

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology, University of Colorado School of Medicine, Aurora.
  1. Correspondence
    Dr. Alvarez enrique.alvarez{at}cuanschutz.edu
View Full Text

Article usage

Article usage: April 2021 to May 2023

AbstractFullPdfSource
Apr 2021698038Highwire
May 20214260141Highwire
Jun 20212100141Highwire
Jul 20211710159Highwire
Aug 202151783121Highwire
Sep 202111793141Highwire
Oct 202128423102Highwire
Nov 20212318451Highwire
Dec 2021915324Highwire
Jan 2022248917Highwire
Feb 2022115723Highwire
Mar 202254714Highwire
Apr 202254714Highwire
May 202243121Highwire
Jun 20222289Highwire
Jul 20222259Highwire
Aug 202272513Highwire
Sep 202244319Highwire
Oct 2022114117Highwire
Nov 202286018Highwire
Dec 202274712Highwire
Jan 202354716Highwire
Feb 20234316Highwire
Mar 20233205Highwire
Apr 20232148Highwire
May 20237169Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles